Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 15/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4918733 | 0.84 | PDK2 (0.48) | PDK2 | |
| SCHEMBL2483545 | 0.81 | PTGS1 (0.41) | PDK2CYP4A11CYP4F2EGFR | |
| SCHEMBL4918215 | 0.78 | PDK2 (0.61) | PDK2CYP4A11CYP4F2EGFR | |
| SCHEMBL4910213 | 0.77 | PDK2 (0.68) | PDK2EGFR | |
| SCHEMBL21135534 | 0.75 | PDK2 (0.61) | PDK2EGFR | |
| SCHEMBL13128005 | 0.74 | PDK2 (1.00) | PDK2 | |
| SCHEMBL4914219 | 0.73 | PDK2 (0.63) | PDK2EGFR | |
| SCHEMBL4910149 | 0.73 | PDK2 (0.59) | PDK2EGFR | |
| SCHEMBL4910868 | 0.72 | PDK2 (0.58) | PDK2 | |
| SCHEMBL26120223 | 0.72 | PDK2 (0.72) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200551-A1 | Flourene Derivative | ASTELLAS PHARMA INC. (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080171788-A1 | Medicament For Irritable Bowel Syndrome | ASTELLAS PHARMA INC. (JP) | 2008-07-17 | — | — | US | disclosed |
| US-20080161419-A1 | Prophylactic Antimigraine Agents | ASTELLAS PHARMA INC. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1852129-A1 | REMEDY FOR IRRITABLE BOWEL SYNDROME | Astellas Pharma Inc. (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1728784-A1 | FLUORENE DERIVATIVE | Astellas Pharma Inc. (JP) | 2006-12-06 | — | — | EP | disclosed |
| EP-1716867-A1 | PREVENTIVES FOR MIGRAINE | Astellas Pharma Inc. (JP) | 2006-11-02 | — | — | EP | disclosed |
| CN-1842517-A | Fluorene derivatives | ASTELLAS PHARMA INC (JP) | 2006-10-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161419-A1 | Prophylactic Antimigraine Agents | HTR2B, HTR7, HTR1A | PDK2 4410/4885CYP4A11 4453/4885CYP4F2 4246/4885 |
| US-20080200551-A1 | Flourene Derivative | HTR2B, HTR7, HTR2C | PDK2 4775/4885CYP4A11 4011/4885CYP4F2 2199/4885 |
| US-20080171788-A1 | Medicament For Irritable Bowel Syndrome | HTR7, HTR5A, HTR3B | PDK2 4110/4885CYP4A11 1931/4885CYP4F2 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.